PDCD1 and melanoma: Despite durability of response, innate resistance to PD-1 inhibition occurs in 30% of melanoma patients4–6 and approximately 25% of responding patients will develop acquired resistance, defined as disease progression following initial objective response, within two years of PD-1 inhibitor treatment4.